Income Statement (TTM)
Nextage Therapeutics Ltd Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 12-31 |
2021 12-31 |
2023 12-31 |
2024 12-31 |
|
|---|---|---|---|---|
| Revenue | 0 | 0 | 1 | 0 |
| Change (%) | -52.36 | 862.64 | -52.85 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 0 | 0 | 1 | 0 |
| Change (%) | 29.31 | 768.00 | -48.23 | |
| % of Revenue | 30.37 | 82.42 | 74.32 | 81.60 |
| Gross Operating Profit | 0 | 0 | 0 | 0 |
| Change (%) | -87.97 | 1,306.25 | -66.22 | |
| % of Revenue | 69.63 | 17.58 | 25.68 | 18.40 |
| SG&A | 6 | 5 | 3 | 3 |
| Change (%) | -9.53 | -36.25 | 4.60 | |
| % of Revenue | 2,937.70 | 5,578.02 | 369.41 | 819.61 |
| R&D | 1 | 0 | ||
| Change (%) | -86.68 | |||
| % of Revenue | 111.42 | 31.48 | ||
| OpEx | 7 | 7 | 5 | 4 |
| Change (%) | 9.49 | -32.57 | -20.79 | |
| % of Revenue | 3,448.69 | 7,925.27 | 555.14 | 932.69 |
| Operating Income | -6 | -7 | -4 | -3 |
| Change (%) | 11.34 | -44.01 | -13.74 | |
| % of Revenue | -3,348.69 | -7,825.27 | -455.14 | -832.69 |
| Interest Expense | -0 | -0 | -0 | -0 |
| Change (%) | 50.00 | -68.55 | -46.00 | |
| % of Revenue | -55.50 | -174.73 | -5.71 | -6.54 |
| Net Income | -16 | -8 | -4 | -3 |
| Change (%) | -51.60 | -49.81 | -15.36 | |
| % of Revenue | -8,359.16 | -8,492.31 | -442.81 | -794.92 |
Source: Capital IQ
